Thyroid hormone resistance: Mechanisms and therapeutic development
- 20 June 2022
- journal article
- research article
- Published by Elsevier in Molecular and Cellular Endocrinology
- Vol. 553, 111679
Abstract
No abstract availableKeywords
This publication has 232 references indexed in Scilit:
- Nuclear receptor corepressor (NCOR1) regulates in vivo actions of a mutated thyroid hormone receptor αProceedings of the National Academy of Sciences, 2013
- In Vivo Activity of the Thyroid Hormone Receptor β- and α-Selective Agonists GC-24 and CO23 on Rat Liver, Heart, and BrainEndocrinology, 2011
- Mutations in the selenocysteine insertion sequence–binding protein 2 gene lead to a multisystem selenoprotein deficiency disorder in humansJournal of Clinical Investigation, 2010
- Structural and functional insights into nuclear receptor signalingAdvanced Drug Delivery Reviews, 2010
- Selenoprotein-Related Disease in a Young Girl Caused by Nonsense Mutations in theSBP2GeneThe Journal of Clinical Endocrinology & Metabolism, 2010
- Resistance to thyroid hormone is associated with raised energy expenditure, muscle mitochondrial uncoupling, and hyperphagiaJournal of Clinical Investigation, 2010
- Gaining ligand selectivity in thyroid hormone receptors via entropyProceedings of the National Academy of Sciences, 2009
- Clinical and Molecular Characterization of a Novel Selenocysteine Insertion Sequence-Binding Protein 2 (SBP2) Gene Mutation (R128X)The Journal of Clinical Endocrinology & Metabolism, 2009
- Targeting thyroid hormone receptor-β agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic indexProceedings of the National Academy of Sciences, 2007
- Regulation of Transcription by a Protein MethyltransferaseScience, 1999